6560 Kennedy Road
230 articles with Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Nadine Jutlah, Interim Chief Financial Officer.
Cipher Pharmaceuticals Inc. today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately.
Cipher Pharmaceuticals Inc. announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities.
Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and twelve months ended December 31st, 2018.
Cipher Pharmaceuticals Inc. announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019.
Cipher Pharmaceuticals Inc. announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada.
Cipher Pharmaceuticals (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ("Synergy") in February 2018.
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET.
Cipher Pharmaceuticals Inc. today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice President, Canadian Commercial Operations.
Canadian product revenue increased 27%
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
Cipher Pharmaceuticals Inc. today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018.
Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibrillation
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market
Canadian product revenue increased 33%
New portfolio royalty extends through December 2024
Cipher Pharmaceuticals Inc. announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018.
Dr. Gajewczyk has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.
Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. was completed.
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced acquisition of Cardiome Pharma Corp.